S. Cappuyns

Clinical factors associated with early disease progression after radioembolization for hepatocellular carcinoma and feasibility of post‐progression systemic therapy

C. Verslype, V. Vandecaveye, C. Deroose, 2022, Liver Cancer International.

Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?

J. Bogaert, L. Michaux, M. Delforge, 2022, European heart journal. Case reports.

DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer

D. Lambrechts, E. Van Cutsem, T. Roskams, 2020, Clinical Epigenetics.

DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer

D. Lambrechts, E. Van Cutsem, T. Roskams, 2020, Clinical Epigenetics.

Combination therapies for advanced hepatocellular carcinoma: biomarkers and unmet needs.

J. Llovet, S. Cappuyns, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma

C. Verslype, B. Beuselinck, J. Dekervel, 2023, Cancers.

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.

J. Llovet, R. Finn, M. Yarchoan, 2023, JAMA oncology.

PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma

D. Lambrechts, B. Boeckx, A. Bassez, 2023, Nature communications.

Applications of single-cell multi-omics in liver cancer

D. Lambrechts, J. Dekervel, S. Cappuyns, 2024, JHEP Reports.